Fig. 1

Effects of CK1-δ inhibitors on the proliferation of lymphoblasts from control and c.709-1G > A GRN mutation carriers individuals. Immortalized lymphocytes from control and carriers of a GRN mutation, asymptomatic or FTLD-TDP patients were seeded at an initial density of 1 × 10⁶ × ml⁻¹ in the absence or in presence of two CK1-δ activity inhibitors, IGS-2.7 and IGS-3.27, for 72 h. a For the MTT assay a total of 100,000 cells per well were seeded in a 96-well plate in presence of increasing doses (0–20 μM) of both drugs. Results represent the % of cell survival of treated cells referred to untreated ones. b Effect of the treatment with IGS-2.7 and IGS-3.27 (5 μM) on proliferation of control and PGRN deficient lymphoblasts. Aliquots were taken for cell counting 72 h after the drug administration. Data shown are the mean ± SEM of 6 independent experiments carried out with all the cell lines used in this studio (**p < 0.01 significantly different from control cells. ††p < 0.01 significantly different from untreated cells; †p < 0.01 significantly different from untreated cells)